SIGA (SIGA) 10-Q 6 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document	9 Months Ended
	Sep. 30, 2013	Oct. 15, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'SIGA TECHNOLOGIES INC	'
Entity Central Index Key	'0001010086	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Trading Symbol	'SIGA	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	53,001,414

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012
ASSETS	'	'
Cash and cash equivalents	$105,190,655	$32,017,490
Accounts receivable	741,918	970,288
Contract receivable, due in next twelve months	451,185	0
Inventory	16,988,019	17,641,922
Prepaid expense and other assets, current	1,061,109	801,149
Deferred tax assets	19,420,266	33,515,327
Total current assets	143,853,152	84,946,176
Property, plant and equipment, net	1,236,373	987,869
Contract receivable	0	3,771,219
Deferred costs	21,887,652	2,841,534
Goodwill	898,334	898,334
Other assets	2,137,433	2,181,720
Deferred tax assets, net	31,556,712	10,209,278
Total assets	201,569,656	105,836,130
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Accounts payable	6,826,552	10,189,917
Accrued expenses and other current liabilities	7,231,697	4,283,849
Common stock warrants, current	1,227,712	333,793
Long-term debt, current maturities	1,963,738	954,738
Total current liabilities	17,249,699	15,762,297
Deferred revenue	162,057,530	57,052,020
Common stock warrants, noncurrent	0	657,246
Long-term debt, excluding current maturities	2,484,086	3,955,262
Other liabilities	454,241	166,303
Total liabilities	182,245,556	77,593,128
Stockholders' equity	'	'
Common stock ($.0001 par value, 100,000,000 shares authorized, 52,396,497 and 51,642,520 issued and outstanding at September 30, 2013, and December 31, 2012, respectively)	5,259	5,164
Additional paid-in capital	171,508,253	167,588,374
Accumulated deficit	-152,189,412	-139,350,536
Total stockholders' equity	19,324,100	28,243,002
Total liabilities and stockholders' equity	$201,569,656	$105,836,130

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Balance Sheet Parenthetical [Abstract]	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	52,593,318	51,642,520
Common stock, shares outstanding	52,593,318	51,642,520

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/LOSS (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues	'	'	'	'
Research and development	$2,292,143	$2,289,820	$4,585,174	$6,456,736
Operating expenses	'	'	'	'
Selling, general and administrative	3,265,735	3,138,711	9,463,233	8,827,280
Research and development	4,260,970	4,170,031	11,037,140	13,817,086
Patent preparation fees	329,054	376,877	1,087,791	1,089,495
Total operating expenses	7,855,759	7,685,619	21,588,164	23,733,861
Operating loss	-5,563,616	-5,395,799	-17,002,990	-17,277,125
Decrease (increase) in fair value of common stock warrants	-734,955	-133,375	-728,865	-228,173
Interest expense	293,438	0	1,043,316	0
Other income, net	5	94	1,489	330
Loss before income taxes	-6,592,004	-5,529,080	-18,773,682	-17,504,968
Benefit from income taxes	1,690,028	2,470,346	5,934,806	6,063,785
Net income (loss)	-4,901,976	-3,058,734	-12,838,876	-11,441,183
Earnings Per Share, Basic and Diluted	($0.09)	($0.06)	($0.25)	($0.22)
Weighted Average Number of Shares Outstanding, Basic and Diluted	52,548,997	51,639,811	52,162,380	51,638,648
Comprehensive income (loss)	'	'	'	'
Change in net unrealized gain (loss) on short-term investments	0	0	0	-4,067
Comprehensive income (loss)	($4,901,976)	($3,058,734)	($12,838,876)	($11,445,250)

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net income (loss)	($12,838,876)	($11,441,183)
Adjustments to reconcile net income (loss) to net cash used in operating activities	'	'
Depreciation and other amortization	319,377	307,708
Increase (decrease) in fair value of warrants	728,865	228,173
Stock based compensation	1,759,074	1,383,770
Amortization of Debt Discount (Premium)	37,824	0
Changes in assets and liabilities:	'	'
Accounts receivable	3,548,404	-1,073,147
Inventory	653,903	-17,357,337
Deferred costs	-19,046,118	-2,147,739
Prepaid expenses and other current assets	-122,200	-318,307
Other assets	122,438	7,501
Deferred income taxes, net	-7,252,373	-6,063,785
Accounts payable, accrued expenses and other liabilities	-415,517	8,873,992
Deferred revenue	105,005,510	2,602,792
Other liabilities	287,938	14,394
Net cash used in operating activities	72,788,249	-24,983,168
Cash flows from investing activities:	'	'
Capital expenditures	-567,881	-263,455
Payment of collateral for commercial surety bond	0	-1,347,956
Net cash (used in) provided by investing activities	-567,881	-1,611,411
Cash flows from financing activities:	'	'
Net proceeds from exercise of warrants and options	1,630,890	9,577
Payment of common stock tendered for employee tax obligations	-178,093	0
Proceeds from issuance of long-term debt	7,000,000	0
Repayments of long-term debt	-7,500,000	0
Net cash provided by financing activities	952,797	9,577
Net increase (decrease) in cash and cash equivalents	73,173,165	-26,585,002
Cash and cash equivalents at beginning of period	32,017,490	49,256,930
Cash and cash equivalents at end of period	$105,190,655	$22,671,928

Interim_Condensed_Consolidated

Interim Condensed Consolidated Financial Statements	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Interim Condensed Consolidated Financial Statements	'
	Condensed Consolidated Financial Statements
	The financial statements are presented in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10-Q and should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2012, included in the 2012 Annual Report on Form 10-K/A. All terms used but not defined elsewhere herein have the meaning ascribed to them in the Company’s 2012 Annual Report on Form 10-K/A filed on May 14, 2013. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results of the interim periods presented have been included. The 2012 year-end balance sheet data was derived from the audited financial statements but does not include all disclosures required by U.S. GAAP. The results of operations for the three and nine months ended September 30, 2013 are not necessarily indicative of the results expected for the full year.
	The financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.
	As of September 30, 2013, the Company has delivered an aggregate of approximately 725,000 courses of Arestvyr™ (tecovirimat), also known as ST-246®, to the U.S. Strategic National Stockpile (the “Strategic Stockpile”). As a result, SIGA has met a key requirement of its procurement contract with the Biomedical Advanced Research and Development Authority (“BARDA”) (refer to Note 2) and received payment of approximately $96 million in the third quarter of 2013 for the courses of product delivered as of September 30, 2013. Management believes that the funds already received in addition to those funds expected to be generated from its procurement contract, together with existing capital resources and continuing government grants and contracts, will be sufficient to support its operations beyond the next twelve months.
	In the fourth quarter of 2013, the Company began an optimization program to sharpen focus and increase efficiencies within its operations. This program, which includes a reduction in employee headcount, is intended to align the Company's resources, staff and efforts with the most promising growth opportunities. With the implementation of the optimization program, the Company is targeting a $6 million reduction in annual operating expenses. As part of the optimization plan, the Company expects to incur restructuring expenses between $500,000 - $800,000. This range includes non-cash charges for assets that may be impaired. Between $275,000 - $350,000 of the anticipated expenses are expected to result in cash outlays.

Procurement_Contract_and_Resea

Procurement Contract and Research Agreements	9 Months Ended
	Sep. 30, 2013
Research and Development [Abstract]	'
Procurement Contract and Research Agreements	'
	Procurement Contract and Research Agreements
	Procurement Contract
	In May 2011, the Company signed a contract with BARDA (the “BARDA Contract”) pursuant to which SIGA agreed to deliver two million courses of Arestvyr to the Strategic Stockpile. The base contract, worth approximately $463 million, includes $54 million related to development and supportive activities and contains various options to be exercised at BARDA’s discretion. The period of performance for development and supportive activities runs until 2020. As originally issued, the BARDA Contract included an option for the purchase of up to 12 million additional courses of Arestvyr; however, following a protest by a competitor of the Company, BARDA issued a contract modification on June 24, 2011 pursuant to which it deleted the option to purchase the additional courses. Under the BARDA Contract as modified, BARDA has agreed to buy from SIGA 1.7 million courses of Arestvyr. Additionally, SIGA will contribute to BARDA 300,000 courses manufactured primarily using federal funds provided by the U.S. Department of Health and Human Services (“HHS”) under prior development contracts. The BARDA Contract as modified also contains options that will permit SIGA to continue its work on pediatric and geriatric versions of the drug as well as use Arestvyr for smallpox prophylaxis. As described in Note 12, the amount of profits SIGA will retain pursuant to the BARDA Contract is subject to the outcome of the litigation in Delaware between SIGA and PharmAthene.
	In the fourth quarter of 2011, SIGA received approximately $41 million in advance payments under the BARDA Contract. In October 2012, SIGA received FDA concurrence with respect to its product labeling strategy in accordance with the BARDA Contract and during the fourth quarter of 2012, the Company received the related milestone payment of approximately $12.3 million. In May 2013, BARDA notified SIGA that the Company had successfully completed the milestone requirements for the Final Drug Product Commercial Validation batches and report and during the second quarter of 2013, the Company received the related milestone payment of approximately $8.2 million. In the third quarter of 2013, the Company received approximately $101 million from BARDA, of which approximately $96 million was for the cumulative delivery of 725,000 courses of Arestvyr and approximately $5 million was for reimbursement related to research and development services and supportive activities.
	The BARDA Contract is a multiple deliverable arrangement including delivery of courses and covered research and development activities. The BARDA Contract provides certain product replacement rights with respect to delivered courses. For this reason, recognition of revenue that might otherwise occur upon delivery of courses is expected to be deferred until the Company’s obligations related to potential replacement of delivered courses are satisfied. The Company assessed the selling price for each of the aforementioned deliverables - research and development activities and drug product. The selling price of certain reimbursed research and development services was determined by reference to existing and past research and development grants and contracts between the Company and various government agencies. The selling price of drug product was determined by reference to other Companies’ sales of drug products such as antiviral therapeutics, orphan drugs and drugs with potential life-saving impact similar to Arestvyr, including products delivered to the Strategic Stockpile.
	In accordance with the authoritative accounting principles, the Company has recognized revenue for reimbursement of certain BARDA Contract research and development services. Cash inflows related to procurement activities will continue to be recorded as deferred revenue. In addition, direct costs incurred by the Company to fulfill the requirements under the BARDA Contract are being deferred and will be recognized as expenses over the same period that the related deferred revenue is recognized as revenue.
	As of September 30, 2013 and December 31, 2012, deferred direct costs under the BARDA Contract of approximately $21.9 million and $2.8 million, respectively, are included in deferred costs on the consolidated balance sheets. As of September 30, 2013, the Company recorded $162.1 million as deferred revenue for the delivery of approximately 725,000 courses of Arestvyr to the Strategic Stockpile in 2013 and certain research and development services provided as part of the BARDA Contract. For the three and nine months ended September 30, 2013, revenue from reimbursed research and development was $913,000.
	Research Agreements
	The Company obtains funding from the contracts and grants it obtains from various agencies of the U.S. Government to support its research and development activities. In addition to the BARDA Contract, the Company currently has one contract and two grants with varying expiration dates through July 2016 that provide for potential future aggregate research and development funding for specific projects of approximately $15.1 million. This amount includes, among other things, options that may or may not be exercised at the U.S. government’s discretion. Moreover, the contract and grants contain customary terms and conditions including the U.S. Government’s right to terminate or restructure a grant for convenience at any time.

Equity_and_Financial_Instrumen

Equity and Financial Instruments (Notes)	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Equity and Financial Instruments	'
	Equity and Financial Instruments
	On June 30, 2013, the Company’s authorized share capital consisted of 110,000,000 shares, of which 100,000,000 are designated common shares and 10,000,000 are designated preferred shares. The Company’s Board of Directors is authorized to issue preferred shares in series with rights, privileges and qualifications of each series determined by the Board.
	At September 30, 2013 and December 31, 2012, the fair market value of outstanding warrants recorded as liabilities was $1,227,712 and $991,039 (revised), respectively. The Company applied the Black-Scholes model to calculate the fair values of the respective derivative instruments using the contractual term of the warrants. Management estimates the expected volatility using a combination of the Company’s historical volatility and the volatility of a group of comparable companies.
	For the three months ended September 30, 2013 and 2012, the Company recorded losses of $734,955 and $133,375 (revised), respectively. For the nine months ended September 30, 2013 and 2012, the Company recorded losses of $728,865 and $228,173 (revised), respectively. The losses are a result of net increases in fair value for warrants outstanding during the respective periods.
	On April 30, 2013, SIGA entered into a Services Agreement with MacAndrews & Forbes LLC (“M&F”) for certain professional and administrative services. The Services Agreement has a term of three years. As consideration for the Services Agreement, SIGA issued warrants to M&F to acquire 250,000 shares of common stock at an exercise price of $3.29 per share. The warrants are fully vested, immediately exercisable and remain exercisable for two years from issuance. As the warrants are immediately exercisable, the grant-date fair value, determined using the Black-Scholes model as previously described, is recorded as an asset with a corresponding increase to equity. The asset is amortized over the contractual term of the warrant.
	2008 Financing
	On June 19, 2008, SIGA entered into a letter agreement, as amended, (the “Letter Agreement”) that expired on June 19, 2010, with M&F, a related party, for M&F’s commitment to invest, at SIGA’s discretion or at M&F’s option, up to $8 million in exchange for (i) SIGA common stock and (ii) warrants to purchase 40% of the number of SIGA shares acquired by M&F. In consideration for the commitment of M&F reflected in the Letter Agreement, on June 19, 2008, M&F received warrants to purchase 238,000 shares of SIGA common stock, initially exercisable at $3.06 (the “Commitment Warrants”). The Commitment Warrants were subject to anti-dilution adjustments and exercisable until June 19, 2012. On June 19, 2012, the Commitment Warrants were amended to extend expiration to June 19, 2014. Due to certain anti-dilution provisions, the Commitment Warrants are recorded as a liability, and consequently the “mark-to-market” adjustment to the fair value from the extended term was accounted for immediately upon modification.
	In 2009, SIGA issued to M&F 816,993 shares of common stock and 326,797 warrants to acquire common stock in exchange for total proceeds of $2.5 million. The warrants were exercisable for a term of four years from issuance and had an exercise price of $3.519 per share, prior to anti-dilution adjustments. In 2013, the warrants issued in 2009 expired.
	On June 18, 2010, M&F notified SIGA of its intention to exercise its right to invest $5.5 million, the remaining amount available under the Letter Agreement following earlier investments and entered into a Deferred Closing and Registration Rights Agreement dated as of June 18, 2010 with the Company. On July 26, 2010, upon satisfaction of certain customary closing conditions, including the expiration of the applicable waiting period pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, M&F funded the $5.5 million purchase price to SIGA in exchange for the issuance of (i) 1,797,386 shares of common stock and (ii) warrants to purchase 718,954 shares of SIGA common stock at an exercise price of $3.519 per share; the warrants are exercisable for a term of four years from issuance.
	The number of shares issuable pursuant to the warrants granted under the Letter Agreement, as well as the exercise price of those warrants, may be subject to adjustment as a result of the effect of future equity issuances on certain anti-dilution provisions in the related warrant agreements.
	2006 Placements
	In 2006, the Company issued 1,000,000 warrants with an initial exercise price of $4.99 per share (the “2006 Warrants”). The 2006 Warrants may be exercised through and including October 19, 2013. At September 30, 2013 and December 31, 2012, 407,784 and 815,568, respectively, of the 2006 Warrants at an exercise price of $2.92 were outstanding. In March 2013, 407,784 of the 2006 Warrants were exercised. The number of shares issuable pursuant to the Warrants may be subject to further adjustment as a result of the effect of future equity issuances on anti-dilution provisions in the related warrant agreements.

Per_Share_Data_Notes

Per Share Data (Notes)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Per Share Data	'
	Per Share Data
	The objective of basic earnings per share (“EPS”) is to measure the performance of an entity over the reporting period by dividing income (loss) by the weighted average shares outstanding. The objective of diluted EPS is consistent with that of basic EPS, except that it also gives effect to all potentially dilutive common shares outstanding during the period.
	The following is a reconciliation of the basic and diluted net income (loss) per share computation:
		Three Months Ended September 30,							Nine Months Ended September 30,
		2013				2012			2013			2012
						(Revised)						(Revised)
	Net income (loss) for basic and diluted EPS	$	(4,901,976	)		$	(3,058,734	)	$	(12,838,876	)	$	(11,441,183	)
	Weighted-average shares for basic and diluted	52,548,997				51,639,811			52,162,380			51,638,648
	Earnings (loss) per share for basic and diluted	$	(0.09	)		$	(0.06	)	$	(0.25	)	$	(0.22	)
	The Company incurred losses for the three and nine months ended September 30, 2013 and 2012 and as a result, certain equity instruments are excluded from the calculation of diluted earnings (loss) per share as the effect of such shares is anti-dilutive. The weighted average number of equity instruments excluded consist of:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013		2012
	Stock Options	2,621,790			2,942,484			2,794,489		2,847,532
	Stock-Settled Stock Appreciation Rights	446,279			462,528			448,694		408,345
	Restricted Stock Units	988,150			460,000			986,692		314,416
	Warrants	1,874,670			2,253,902			1,980,623		2,266,774
	The appreciation of each stock-settled stock appreciation right was capped at a determined maximum value. As a result, the weighted average number shown in the table above for stock-settled stock appreciation rights reflects the weighted average maximum number of shares that could be issued.

Fair_Value_Measurements_Notes

Fair Value Measurements (Notes)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures	'
	The carrying value of cash and cash equivalents, accounts payable and accrued expenses approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as liabilities are recorded at their fair market value as of each reporting period.
	The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy:
	•	Level 1 – Quoted prices for identical instruments in active markets.
	•	Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.
	•	Level 3 – Instruments where significant value drivers are unobservable to third parties.
	The Company uses model-derived valuations where inputs are observable in active markets to determine the fair value of certain common stock warrants on a recurring basis and classify such warrants in Level 2. The Company utilizes the Black-Scholes model consisting of the following variables: (i) the closing price of SIGA’s common stock; (ii) the expected remaining life of the warrant; (iii) the expected volatility using a weighted-average of historical volatilities from a combination of SIGA and comparable companies; and (iv) the risk-free market rate. At September 30, 2013 and December 31, 2012, the fair value of liability classified warrants was as follows:
		30-Sep-13		31-Dec-12
				(Revised)
	Common stock warrants, current	$	1,227,712	$	333,793
	Common stock warrants, non-current	—		657,246
		$	1,227,712	$	991,039
	At September 30, 2013 and December 31, 2012, the Company also had $4.5 million and $5.0 million in outstanding debt, respectively. The fair value of this debt is a Level 2 measurement. The fair value of the loan approximates carrying value at September 30, 2013. For the three and nine months ended September 30, 2013 and 2012, SIGA did not hold any Level 3 securities.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Related Party Transactions
	On December 1, 2009, the Company entered into an Office Services Agreement with an affiliate of M&F to occupy office space for approximately $8,000 per month. An amendment in February 2012 increased the monthly payment to $12,000 to appropriately reflect expanded use of space. The Office Services Agreement was canceled effective March 31, 2013.
	In October 2012, the Company funded a letter of credit and deposit to take advantage of a lease for office space secured by an affiliate of M&F from a third party landlord on behalf of the Company. Pursuant to such letter of credit, in January 2013 the Company entered into a sublease in which the Company will pay all costs associated with the lease, including rent. All payments made by the Company pursuant to the sublease will either be directly or indirectly made to the third-party landlord and not retained by M&F or any affiliate. The new sublease replaced the Office Services Agreement that is described in the previous paragraph, and occupancy commenced on April 1, 2013. The sublease allowed for a free rent period of five months beginning April 1, 2013; subsequent to the free rent period, monthly rent payments are $60,000 for the first five years and $63,000 for the next two years. Rent payments under the lease and sublease are subject to customary rent escalation clauses.
	In April 2013, the Company entered into a Services Agreement with M&F and a warrant agreement with M&F (refer to Note 3).
	A member of the Company’s Board of Directors is a member of the Company’s outside counsel. During the nine months ended September 30, 2013 and 2012, the Company incurred costs of $1.0 million and $1.3 million, respectively, related to services provided by the outside counsel. On September 30, 2013, the Company’s outstanding payables included $147,000 payable to the outside counsel.

Inventory_Notes

Inventory (Notes)	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventory	'
	Inventory
	As of September 30, 2013 and December 31, 2012, the Company has $17.0 million and $17.6 million of work-in-process inventory, respectively. During the nine months ended September 30, 2013, the Company delivered approximately 725,000 courses to the Strategic Stockpile; due to the deferral of revenue under the BARDA Contract (refer to Note 2), amounts that would be otherwise recorded as cost of goods sold for delivered courses are recorded as deferred costs in the balance sheet. The value of in-process inventory represents the costs incurred to manufacture Arestvyr under the BARDA Contract. Certain of the existing units of Arestvyr were initially manufactured prior to the point at which future commercialization was probable; thus, such cost was expensed as research and development in those respective periods. Additional costs incurred to complete production of courses of Arestvyr will be recorded as inventory and reclassified to deferred costs upon delivery to the extent related revenue is deferred.

Property_Plant_and_Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment	'
	Property, Plant and Equipment
	Property, plant and equipment consisted of the following:
		September 30, 2013			December 31, 2012
	Laboratory equipment	$	2,440,045		$	2,305,410
	Leasehold improvements	3,006,310			2,817,123
	Computer equipment	559,599			458,421
	Furniture and fixtures	488,168			345,287
		6,494,122			5,926,241
	Less - accumulated depreciation	(5,257,749		)	(4,938,372		)
	Property, plant and equipment, net	$	1,236,373		$	987,869

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Accrued Expenses and Other Current Liabilities	'
	Accrued Expenses
	Accrued expenses and other current liabilities consisted of the following:
		September 30, 2013		31-Dec-12
	Loss contingency	$	2,598,322	$	2,491,981
	Bonus	1,096,635		250,000
	Professional fees	782,213		579,609
	Vacation	337,452		328,463
	Other	2,417,075		633,796
	Accrued expenses and other current liabilities	$	7,231,697	$	4,283,849

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax	'
	Income Taxes
	Deferred tax assets, net were $51.0 million on September 30, 2013 and $43.7 million on December 31, 2012, respectively, net of valuation allowances of $4.3 million and $4.3 million, respectively. For the three and nine months ended September 30, 2013, the Company incurred net losses consequently recognized an income tax benefit of $1.7 million and $5.9 million, respectively. For the three and nine months ended September 30, 2012, the Company incurred net losses and consequently recognized an income tax benefit of $2.5 million and $6.1 million, respectively. For the three months ended September 30, 2013, the Company recorded tax payable of $1.3 million for estimated alternative minimum tax at September 30, 2013. The Company expects to pay approximately $1.4 million of alternative minimum tax in the fourth quarter of 2013.
	The recognition of a valuation allowance for deferred taxes requires management to make estimates and judgments about the Company’s future profitability which are inherently uncertain. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. If the current estimates of future taxable income are reduced or not realized, for example, based on the outcome of the PharmAthene litigation described in Note 12, the Company’s assessment regarding the realization of deferred tax assets could change. Future changes in the estimated amount of deferred taxes expected to be realized will be reflected in the Company’s financial statements in the period the estimate is changed with a corresponding adjustment to operating results. Changes in estimates may occur often and can have a significant favorable or unfavorable impact on the Company’s operating results from period to period.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements (Notes)	9 Months Ended
	Sep. 30, 2013
Recent Accounting Pronouncements [Abstract]	'
New Accounting Pronouncements, Policy	'
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (“FASB”) issued new guidance on the reporting of reclassifications from accumulated other comprehensive income to net income. The new guidance does not change the requirements for reporting net income or other comprehensive income in financial statements but requires disclosures regarding the reclassification of accumulated other comprehensive income by component into net income. The Company’s adoption of this guidance on January 2, 2013 did not have a material effect on our financial statements.
	In July 2013, the FASB issued new guidance on the financial statement presentation of unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The new guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not anticipate a material impact to the Company’s financial position, results of operations or cash flows as a result of this change.

Legal_Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Legal Proceedings
	In December 2006, PharmAthene, Inc. (“PharmAthene”) filed an action against SIGA in the Delaware Court of Chancery (the “Court” or “Court of Chancery”) captioned PharmAthene, Inc. v. SIGA Technologies, Inc., C.A. No. 2627-N. In its amended complaint, PharmAthene asked the Court to order the Company to enter into a license agreement with PharmAthene with respect to ST-246, now also known as Arestvyr, to declare that the Company is obliged to execute such a license agreement, and to award damages resulting from the Company’s supposed breach of that obligation. PharmAthene also alleged that the Company breached an obligation to negotiate such a license agreement in good faith, and sought damages for promissory estoppel and unjust enrichment based on supposed information, capital, and assistance that PharmAthene allegedly provided to the Company during the negotiation process. The Court tried the case in January 2011.
	In September 2011, the Court issued its post-trial opinion. The Court denied PharmAthene’s requests for specific performance and expectation damages measured by the present value of estimated future profits. Nevertheless, the Court held that the Company breached its duty to negotiate in good faith and was liable under the doctrine of promissory estoppel. The Court consequently awarded to PharmAthene what the Court described as an equitable payment stream or equitable lien consisting of fifty percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale. In addition, the Court awarded PharmAthene one-third of its reasonable attorneys’ fees and expert witness expenses.
	In May 2012, the Court entered its final order and judgment in this matter, implementing its post-trial opinion. Among other things, the final order and judgment provided that (a) net profits would be calculated in accordance with generally accepted accounting principles applied consistently with how they are applied in the preparation of the Company’s financial statements, (b) the net profits calculation would take into account expenses relating to ST-246 commencing with the Company’s acquisition of ST-246 in August 2004, and (c) PharmAthene could recover $2.4 million of attorneys’ fees and expenses. As of September 30, 2013, SIGA has recorded a $2.6 million loss contingency with respect to the fee, expense and interest portion of the judgment.
	In June 2012, the Company appealed to the Supreme Court of the State of Delaware the final order and judgment and certain earlier rulings of the Court of Chancery. Shortly thereafter, PharmAthene filed its cross-appeal. The Company obtained a stay of enforcement of the fee and expense portion of the judgment by filing a surety bond for the amount of the judgment plus post-judgment interest. The Company posted $1.3 million as collateral for the surety bond which is recorded in other assets as of September 30, 2013. The parties briefed the issues, and argued before the Delaware Supreme Court, en banc, on January 10, 2013.
	On May 24, 2013, the Supreme Court of Delaware issued its decision, affirming the Delaware Court of Chancery’s judgment in part, reversing it in part, and remanding to Vice Chancellor Parsons. The Supreme Court affirmed the Chancery Court determination that the Company had breached its contractual obligation to negotiate in good faith; reversed the promissory estoppel holding; and, reversed the Vice Chancellor’s equitable damages award. The Supreme Court held that the trial judge may award expectation damages for breach of the contractual duty to negotiate in good faith if such damages are proven with reasonable certainty, and remanded to the Chancery Court for consideration of damages consistent with that holding. The Supreme Court also reversed the Chancery Court’s award of attorney fees and expert witness fees because they were predicated in part on a now-reversed finding of liability on PharmAthene’s promissory estoppel claim. The Supreme Court held that the Chancery Court could reevaluate on remand an alternative award, if any, of attorneys’ fees and expert testimony expenses consistent with the Supreme Court’s opinion. Finally, the Supreme Court declined to consider all claims raised in PharmAthene’s cross appeal because it affirmed the Chancery Court’s finding that the Company was liable for breaching its contractual obligation to negotiate in good faith. On June 11, 2013, the Supreme Court issued its mandate to the Court of Chancery with the decision described above.
	On June 26, 2013, the parties appeared before Vice Chancellor Parsons to discuss the remand, at which time PharmAthene declared its desire to supplement the record with further evidence. Following briefing and argument on August 15, 2013, the Chancery Court granted PharmAthene’s motion to supplement the record and also allowed the Company to submit responsive evidence. A hearing with respect to that evidence has been scheduled and a briefing schedule has also been fixed leading to oral argument on the issue of what if any remedy the Chancery Court should impose in light of the remand by the Supreme Court of Delaware.
	No assurances can be given as to the Chancery Court’s determinations on remand.
	From time to time, the Company is involved in disputes or legal proceedings arising in the ordinary course of business. The Company believes that there is no dispute or litigation pending, except as discussed above, that could have, individually or in the aggregate, a material adverse effect on its financial position, results of operations or cash flows.

Revision_of_Consolidated_Finan

Revision of Consolidated Financial Statements (Notes)	9 Months Ended
	Sep. 30, 2013
Revision of Consolidated Financial Statements [Abstract]	'
Accounting Changes and Error Corrections	'
	13. Revision of Consolidated Financial Statements
	Subsequent to the issuance of its annual report on Form 10-K for the year ended December 31, 2012 as filed on March 6, 2013, the Company determined certain outstanding warrants to purchase common stock of the Company (the “Warrants”) should have been recorded as liabilities rather than equity and that non-cash charges resulting from required periodic “mark-to-market” adjustments of the Warrants also should have been recorded. For the year ended December 31, 2012 and the quarters therein, the quantitative and qualitative impact of the non-cash adjustments on net loss were not material and consequently, the Company revised prior period amounts as disclosed within the Form 10-K/A filed on May 14, 2013. As these are non-cash items, there is no impact to net cash used in operations for the three and nine months ended September 30, 2012.
	The effects of the revision on the unaudited financial statements are summarized below:
		31-Dec-12
		As Originally Reported			Adjustments			Revised
	ASSETS
	Current assets
	Cash and cash equivalents	$	32,017,490					$	32,017,490
	Accounts receivable	970,288						970,288
	Inventory	17,641,922						17,641,922
	Prepaid expenses and other current assets	801,149						801,149
	Deferred tax assets, net	33,515,327						33,515,327
	Total current assets	84,946,176						84,946,176
	Property, plant and equipment, net	987,869						987,869
	Receivables from long-term contract	3,771,219						3,771,219
	Deferred costs	2,841,534						2,841,534
	Goodwill	898,334						898,334
	Other assets	2,181,720						2,181,720
	Deferred tax assets, net	10,209,278						10,209,278
	Total assets	$	105,836,130		$	—		$	105,836,130
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Current liabilities
	Accounts payable	$	10,189,917					$	10,189,917
	Accrued expenses and other current liabilities	4,283,849						4,283,849
	Current common stock warrants	287,036			46,757			333,793
	Current portion of long term debt	954,738						954,738
	Total current liabilities	15,715,540			46,757			15,762,297
	Deferred revenue	57,052,020						57,052,020
	Common stock warrants	—			657,246			657,246
	Long term debt	3,955,262						3,955,262
	Other liabilities	166,303						166,303
	Total liabilities	76,889,125			704,003			77,593,128
	Stockholders’ equity
	Common stock	5,164						5,164
	Additional paid-in capital	152,340,303			15,248,071			167,588,374
	Accumulated deficit	(123,398,462		)	(15,952,074		)	(139,350,536		)
	Total stockholders’ equity	28,947,005			(704,003		)	28,243,002
	Total liabilities and stockholders’ equity	$	105,836,130		$	—		$	105,836,130
		Three Months Ended September 30, 2012
		As Originally Reported			Adjustments			Revised
	Revenues
	Research and development	$	2,289,820					$	2,289,820
	Operating expenses
	Selling, general and administrative	3,138,711						3,138,711
	Research and development	4,170,031						4,170,031
	Patent preparation fees	376,877						376,877
	Total operating expenses	7,685,619			—			7,685,619
	Operating loss	(5,395,799		)	—			(5,395,799		)
	Decrease (increase) in fair value of common stock warrants	(15,032		)	(118,343		)	(133,375		)
	Other income, net	94						94
	Loss before benefit from income taxes	(5,410,737		)	(118,343		)	(5,529,080		)
	Benefit from income taxes	2,470,346						2,470,346
	Net income (loss)	$	(2,940,391	)	$	(118,343	)	$	(3,058,734	)
	Basic and diluted earnings (loss) per share	$	(0.06	)	$	—		$	(0.06	)
	Weighted average shares outstanding: basic and diluted	51,639,811			—			51,639,811
		Nine Months Ended September 30, 2012
		As Originally Reported			Adjustments			Revised
	Revenues
	Research and development	$	6,456,736					$	6,456,736
	Operating expenses
	Selling, general and administrative	8,827,280						8,827,280
	Research and development	13,817,086						13,817,086
	Patent preparation fees	1,089,495						1,089,495
Total operating expenses	23,733,861			—			23,733,861
Operating loss	(17,277,125		)	—			(17,277,125		)
Decrease (increase) in fair value of common stock warrants	(126,833		)	(101,340		)	(228,173		)
Other income, net	330						330
Loss before benefit from income taxes	(17,403,628		)	(101,340		)	(17,504,968		)
Benefit from income taxes	6,063,785						6,063,785
Net income (loss)	$	(11,339,843	)	$	(101,340	)	$	(11,441,183	)
Basic and diluted earnings (loss) per share	$	(0.22	)	$	—		$	(0.22	)
Weighted average shares outstanding: basic and diluted	51,638,648			—			51,638,648

Per_Share_Data_Tables

Per Share Data (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Schedule of earnings per share, basic and diluted	'
	The following is a reconciliation of the basic and diluted net income (loss) per share computation:
		Three Months Ended September 30,							Nine Months Ended September 30,
		2013				2012			2013			2012
						(Revised)						(Revised)
	Net income (loss) for basic and diluted EPS	$	(4,901,976	)		$	(3,058,734	)	$	(12,838,876	)	$	(11,441,183	)
	Weighted-average shares for basic and diluted	52,548,997				51,639,811			52,162,380			51,638,648
	Earnings (loss) per share for basic and diluted	$	(0.09	)		$	(0.06	)	$	(0.25	)	$	(0.22	)
Schedule of antidilutive securities excluded from computation of earnings per share	'
	The Company incurred losses for the three and nine months ended September 30, 2013 and 2012 and as a result, certain equity instruments are excluded from the calculation of diluted earnings (loss) per share as the effect of such shares is anti-dilutive. The weighted average number of equity instruments excluded consist of:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013		2012
	Stock Options	2,621,790			2,942,484			2,794,489		2,847,532
	Stock-Settled Stock Appreciation Rights	446,279			462,528			448,694		408,345
	Restricted Stock Units	988,150			460,000			986,692		314,416
	Warrants	1,874,670			2,253,902			1,980,623		2,266,774

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, plant and equipment	'
	Property, plant and equipment consisted of the following:
		September 30, 2013			December 31, 2012
	Laboratory equipment	$	2,440,045		$	2,305,410
	Leasehold improvements	3,006,310			2,817,123
	Computer equipment	559,599			458,421
	Furniture and fixtures	488,168			345,287
		6,494,122			5,926,241
	Less - accumulated depreciation	(5,257,749		)	(4,938,372		)
	Property, plant and equipment, net	$	1,236,373		$	987,869

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Accrued Expenses and Other Current Liabilities	'
	Accrued expenses and other current liabilities consisted of the following:
		September 30, 2013		31-Dec-12
	Loss contingency	$	2,598,322	$	2,491,981
	Bonus	1,096,635		250,000
	Professional fees	782,213		579,609
	Vacation	337,452		328,463
	Other	2,417,075		633,796
	Accrued expenses and other current liabilities	$	7,231,697	$	4,283,849

Revision_of_Consolidated_Finan1

Revision of Consolidated Financial Statements (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule of Condensed Balance Sheet	'
		31-Dec-12
		As Originally Reported			Adjustments			Revised
	ASSETS
	Current assets
	Cash and cash equivalents	$	32,017,490					$	32,017,490
	Accounts receivable	970,288						970,288
	Inventory	17,641,922						17,641,922
	Prepaid expenses and other current assets	801,149						801,149
	Deferred tax assets, net	33,515,327						33,515,327
	Total current assets	84,946,176						84,946,176
	Property, plant and equipment, net	987,869						987,869
	Receivables from long-term contract	3,771,219						3,771,219
	Deferred costs	2,841,534						2,841,534
	Goodwill	898,334						898,334
	Other assets	2,181,720						2,181,720
	Deferred tax assets, net	10,209,278						10,209,278
	Total assets	$	105,836,130		$	—		$	105,836,130
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Current liabilities
	Accounts payable	$	10,189,917					$	10,189,917
	Accrued expenses and other current liabilities	4,283,849						4,283,849
	Current common stock warrants	287,036			46,757			333,793
	Current portion of long term debt	954,738						954,738
	Total current liabilities	15,715,540			46,757			15,762,297
	Deferred revenue	57,052,020						57,052,020
	Common stock warrants	—			657,246			657,246
	Long term debt	3,955,262						3,955,262
	Other liabilities	166,303						166,303
	Total liabilities	76,889,125			704,003			77,593,128
	Stockholders’ equity
	Common stock	5,164						5,164
	Additional paid-in capital	152,340,303			15,248,071			167,588,374
	Accumulated deficit	(123,398,462		)	(15,952,074		)	(139,350,536		)
	Total stockholders’ equity	28,947,005			(704,003		)	28,243,002
	Total liabilities and stockholders’ equity	$	105,836,130		$	—		$	105,836,130
Schedule of Condensed Income Statement	'
		Nine Months Ended September 30, 2012
		As Originally Reported			Adjustments			Revised
	Revenues
	Research and development	$	6,456,736					$	6,456,736
	Operating expenses
	Selling, general and administrative	8,827,280						8,827,280
	Research and development	13,817,086						13,817,086
	Patent preparation fees	1,089,495						1,089,495
	Total operating expenses	23,733,861			—			23,733,861
	Operating loss	(17,277,125		)	—			(17,277,125		)
	Decrease (increase) in fair value of common stock warrants	(126,833		)	(101,340		)	(228,173		)
	Other income, net	330						330
	Loss before benefit from income taxes	(17,403,628		)	(101,340		)	(17,504,968		)
	Benefit from income taxes	6,063,785						6,063,785
	Net income (loss)	$	(11,339,843	)	$	(101,340	)	$	(11,441,183	)
	Basic and diluted earnings (loss) per share	$	(0.22	)	$	—		$	(0.22	)
	Weighted average shares outstanding: basic and diluted	51,638,648			—			51,638,648
		Three Months Ended September 30, 2012
		As Originally Reported			Adjustments			Revised
	Revenues
	Research and development	$	2,289,820					$	2,289,820
	Operating expenses
	Selling, general and administrative	3,138,711						3,138,711
	Research and development	4,170,031						4,170,031
	Patent preparation fees	376,877						376,877
	Total operating expenses	7,685,619			—			7,685,619
	Operating loss	(5,395,799		)	—			(5,395,799		)
	Decrease (increase) in fair value of common stock warrants	(15,032		)	(118,343		)	(133,375		)
	Other income, net	94						94
	Loss before benefit from income taxes	(5,410,737		)	(118,343		)	(5,529,080		)
	Benefit from income taxes	2,470,346						2,470,346
	Net income (loss)	$	(2,940,391	)	$	(118,343	)	$	(3,058,734	)
	Basic and diluted earnings (loss) per share	$	(0.06	)	$	—		$	(0.06	)
	Weighted average shares outstanding: basic and diluted	51,639,811			—			51,639,811

Interim_Condensed_Consolidated1

Interim Condensed Consolidated Financial Statements Organization, Consolidation and Presentation (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
	course
Restructuring Reserve Disclosures [Line Items]	'
Restructuring and related cost, expected expense reduction	$6,000,000
Procurement Contract [Abstract]	'
Number of courses delivered	725,000
Contract receivable collected, delivered product	96,000,000
Minimum	'
Restructuring Reserve Disclosures [Line Items]	'
Restructuring and related cost, expected cost	500,000
Restructuring and related cost, expected cash outlays	275,000
Maximum	'
Restructuring Reserve Disclosures [Line Items]	'
Restructuring and related cost, expected cost	800,000
Restructuring and related cost, expected cash outlays	$350,000

Procurement_Contract_and_Resea1

Procurement Contract and Research Agreements (Details) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended
	Jun. 24, 2011	31-May-11	Dec. 31, 2012	Dec. 31, 2011	Jun. 30, 2013	Sep. 30, 2013
	course	course				course
Procurement Contract [Line Items]	'	'	'	'	'	'
Contract receivable collected, delivered product	'	'	'	'	'	$96,000,000
Number of courses delivered	'	'	'	'	'	725,000
Research and development revenue long-term contract	'	'	'	'	'	913,000
Contract receivable collected, research and developemnt services	'	'	'	'	'	5,000,000
Deferred costs	'	'	2,841,534	'	'	21,887,652
Number of active contracts	'	'	'	'	'	1
Number of active grants	'	'	'	'	'	2
BARDA Contract	'	'	'	'	'	'
Procurement Contract [Line Items]	'	'	'	'	'	'
Number of courses to be delivered	'	2,000,000	'	'	'	'
Value of contract	'	463,000,000	'	'	'	'
Contract value of development and support activities	'	54,000,000	'	'	'	'
Option to purchase additional courses	'	12,000,000	'	'	'	'
Number of courses under modified contract	1,700,000	'	'	'	'	'
Number of courses manufactured using federal funds	300,000	'	'	'	'	'
Proceeds from advance payments under the BARDA contract	'	'	'	41,000,000	'	'
Milestone payment	'	'	12,300,000	'	8,200,000	'
Contract receivable collected, long term contract	'	'	'	'	'	101,000,000
Contract receivable collected, delivered product	'	'	'	'	'	96,000,000
Number of courses delivered	'	'	'	'	'	725,000
Deferred costs	'	'	2,841,534	'	'	21,887,652
Deferred revenue, additions from BARDA contract	'	'	'	'	'	162,100,000
Potential future research and development funding	'	'	'	'	'	$15,100,000

Equity_and_Financial_Instrumen1

Equity and Financial Instruments (Details) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

12 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Mar. 31, 2013

Dec. 31, 2012

Dec. 31, 2006

Apr. 30, 2013

Jun. 18, 2010

Dec. 31, 2009

Jun. 19, 2008

Jun. 19, 2008

Sep. 30, 2013

Dec. 31, 2012

Affiliated Entity

Affiliated Entity

Affiliated Entity

Affiliated Entity

Extended Expiration Period [Member]

Fair Value, Measurements, Recurring [Member]

Fair Value, Measurements, Recurring [Member]

Affiliated Entity

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock warrants, current and noncurrent

'

'

'

'

'

'

'

'

'

'

'

'

$1,227,712

$991,039

Change In fair value of common stock warrants

-734,955

-133,375

-728,865

-228,173

'

'

'

'

'

'

'

'

'

'

Service agreement term

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

Warrants to purchase common stock

'

'

'

'

'

'

1,000,000

250,000

718,954

326,797

'

238,000

'

'

Exercise price of warrants to purchase common stock

2.92

'

2.92

'

'

'

4.99

3.29

3.519

3.519

'

3.06

'

'

Warrants contractual term (in years)

'

'

'

'

'

'

'

'2 years

'4 years

'4 years

'

'

'

'

Commitment to Invest

'

'

'

'

'

'

'

'

'

'

8,000,000

'

'

'

Warrants to purchase percentage of acquired shares

'

'

'

'

'

'

'

'

'

'

40.00%

'

'

'

Common stock, shares issued

52,593,318

'

52,593,318

'

'

51,642,520

'

'

1,797,386

816,993

'

'

'

'

Proceeds from issuance of warrants and options

'

'

'

'

'

'

'

'

$5,500,000

$2,500,000

'

'

'

'

Warrants exercised

'

'

'

'

407,784

'

'

'

'

'

'

'

'

'

Warrants, outstanding

407,784

'

407,784

'

'

815,568

'

'

'

'

'

'

'

'

Capital units, authorized

110,000,000

'

110,000,000

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

100,000,000

'

100,000,000

'

'

100,000,000

'

'

'

'

'

'

'

'

Preferred stock, shares authorized

10,000,000

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

Per_Share_Data_Details

Per Share Data (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Net income (loss)	($4,901,976)	($3,058,734)	($12,838,876)	($11,441,183)
Weighted average number of shares outstanding, basic and diluted	52,548,997	51,639,811	52,162,380	51,638,648
Earnings Per Share, Basic and Diluted	($0.09)	($0.06)	($0.25)	($0.22)
Stock Options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted average number	2,621,790	2,942,484	2,794,489	2,847,532
Stock Appreciation Rights (SARs) [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted average number	446,279	462,528	448,694	408,345
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted average number	988,150	460,000	986,692	314,416
Warrants [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted average number	1,874,670	2,253,902	1,980,623	2,266,774

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Common stock warrants, current	$1,227,712	$333,793
Common stock warrants, noncurrent	0	657,246
Term loan	4,500,000	5,000,000
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Common stock warrants, current	'	333,793
Common stock warrants, noncurrent	'	657,246
Common stock warrants, current and noncurrent	$1,227,712	$991,039

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	9 Months Ended			9 Months Ended
	Sep. 30, 2013	Feb. 29, 2012	Dec. 01, 2009	Sep. 30, 2013	Sep. 30, 2012
	Affiliated Entity	Affiliated Entity	Affiliated Entity	Member of Board of Directors	Member of Board of Directors
Related Party Transaction [Line Items]	'	'	'	'	'
Lease property price per month	'	$12,000	$8,000	'	'
Free rent period	'5 months	'	'	'	'
Monthly rental payments first five years	60,000	'	'	'	'
Initial rent period	'5 years	'	'	'	'
Monthly rental payments after five years	63,000	'	'	'	'
Rent period after first five years	'2 years	'	'	'	'
Legal fees	'	'	'	1,000,000	1,300,000
Accounts payable to related party	'	'	'	$147,000	'

Inventory_Details

Inventory (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013
			BARDA Contract
			course
Procurement Contract [Line Items]	'	'	'
Courses delivered	'	'	725,000
Inventory	$16,988,019	$17,641,922	'

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]	'	'
Laboratory Equipment, Gross	$2,440,045	$2,305,410
Leasehold Improvements, Gross	3,006,310	2,817,123
Computer Equipment, Gross	559,599	458,421
Furniture and Fixtures, Gross	488,168	345,287
Property, Plant and Equipment, Gross	6,494,122	5,926,241
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	-5,257,749	-4,938,372
Property, Plant and Equipment, Net	$1,236,373	$987,869

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Payables and Accruals [Abstract]	'	'
Loss contingency	$2,598,322	$2,491,981
Bonus	1,096,635	250,000
Professional fees	782,213	579,609
Vacation	337,452	328,463
Other	2,417,075	633,796
Total	$7,231,697	$4,283,849

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'	'	'	'
Deferred tax assets, net of valuation allowance	$51,000,000	'	$51,000,000	'	$43,700,000
Deferred tax assets, valuation allowance	4,300,000	'	4,300,000	'	4,300,000
Benefit from income taxes	1,690,028	2,470,346	5,934,806	6,063,785	'
Taxes payable	1,300,000	'	1,300,000	'	'
Tax payment, expected	'	'	$1,400,000	'	'

Legal_Proceedings_Details

Legal Proceedings (Details) (License Agreement litigation, Pending litigation, USD $)	1 Months Ended
	Sep. 30, 2011	Sep. 30, 2013	31-May-12
Loss Contingencies [Line Items]	'	'	'
Percentage of net profits from sales after net profit threshold	'	50.00%	'
Net profit threshold	'	$40,000,000	'
Equitable payment stream following first commercial sale, duration	'10 years	'	'
Percentage of litigation costs awarded	33.00%	'	'
Plaintiff attorneys' fee and expenses	'	'	2,400,000
Accrued liabilities	'	'	'
Loss Contingencies [Line Items]	'	'	'
Accrued liabilities, current	'	2,600,000	'
Surety bond | Other assets	'	'	'
Loss Contingencies [Line Items]	'	'	'
Payment to post collateral for surety bond	'	$1,300,000	'

Revision_of_Consolidated_Finan2

Revision of Consolidated Financial Statements Restatement (Details) - Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Cash and Cash Equivalents, at Carrying Value	$105,190,655	$32,017,490	$22,671,928	$49,256,930
Accounts receivable	741,918	970,288	'	'
Inventory	16,988,019	17,641,922	'	'
Prepaid expense and other assets, current	1,061,109	801,149	'	'
Deferred tax assets	19,420,266	33,515,327	'	'
Total current assets	143,853,152	84,946,176	'	'
Property, Plant and Equipment, net	1,236,373	987,869	'	'
Contract receivable	0	3,771,219	'	'
Deferred costs	21,887,652	2,841,534	'	'
Goodwill	898,334	898,334	'	'
Other assets	2,137,433	2,181,720	'	'
Deferred tax assets, net	31,556,712	10,209,278	'	'
Total assets	201,569,656	105,836,130	'	'
Accounts payable	6,826,552	10,189,917	'	'
Accrued expenses and other current liabilities	7,231,697	4,283,849	'	'
Common stock warrants, current	1,227,712	333,793	'	'
Long-term debt, current maturities	1,963,738	954,738	'	'
Total current liabilities	17,249,699	15,762,297	'	'
Deferred revenue	162,057,530	57,052,020	'	'
Common stock warrants, noncurrent	0	657,246	'	'
Long-term debt, excluding current maturities	2,484,086	3,955,262	'	'
Other liabilities	454,241	166,303	'	'
Total liabilities	182,245,556	77,593,128	'	'
Common Stock, Value, Issued	5,259	5,164	'	'
Additional paid-in capital	171,508,253	167,588,374	'	'
Accumulated deficit	-152,189,412	-139,350,536	'	'
Total stockholders' equity	19,324,100	28,243,002	'	'
Total liabilities and stockholders' equity	201,569,656	105,836,130	'	'
As Originally Reported	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	'	32,017,490	'	'
Accounts receivable	'	970,288	'	'
Inventory	'	17,641,922	'	'
Prepaid expense and other assets, current	'	801,149	'	'
Deferred tax assets	'	33,515,327	'	'
Total current assets	'	84,946,176	'	'
Property, Plant and Equipment, net	'	987,869	'	'
Contract receivable	'	3,771,219	'	'
Deferred costs	'	2,841,534	'	'
Goodwill	'	898,334	'	'
Other assets	'	2,181,720	'	'
Deferred tax assets, net	'	10,209,278	'	'
Total assets	'	105,836,130	'	'
Accounts payable	'	10,189,917	'	'
Accrued expenses and other current liabilities	'	4,283,849	'	'
Common stock warrants, current	'	287,036	'	'
Long-term debt, current maturities	'	954,738	'	'
Total current liabilities	'	15,715,540	'	'
Deferred revenue	'	57,052,020	'	'
Common stock warrants, noncurrent	'	0	'	'
Long-term debt, excluding current maturities	'	3,955,262	'	'
Other liabilities	'	166,303	'	'
Total liabilities	'	76,889,125	'	'
Common Stock, Value, Issued	'	5,164	'	'
Additional paid-in capital	'	152,340,303	'	'
Accumulated deficit	'	-123,398,462	'	'
Total stockholders' equity	'	28,947,005	'	'
Total liabilities and stockholders' equity	'	105,836,130	'	'
Adjustments	'	'	'	'
Total assets	'	0	'	'
Common stock warrants, current	'	46,757	'	'
Total current liabilities	'	46,757	'	'
Common stock warrants, noncurrent	'	657,246	'	'
Total liabilities	'	704,003	'	'
Additional paid-in capital	'	15,248,071	'	'
Accumulated deficit	'	-15,952,074	'	'
Total stockholders' equity	'	-704,003	'	'
Total liabilities and stockholders' equity	'	$0	'	'

Revision_of_Consolidated_Finan3

Revision of Consolidated Financial Statements Restatement (Details) - Condensed Consolidated Statement of Operations (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Research and development	$2,292,143	$2,289,820	$4,585,174	$6,456,736
Selling, general and administrative	3,265,735	3,138,711	9,463,233	8,827,280
Research and development	4,260,970	4,170,031	11,037,140	13,817,086
Patent preparation fees	329,054	376,877	1,087,791	1,089,495
Total operating expenses	7,855,759	7,685,619	21,588,164	23,733,861
Operating loss	-5,563,616	-5,395,799	-17,002,990	-17,277,125
Change In fair value of common stock warrants	-734,955	-133,375	-728,865	-228,173
Other income, net	5	94	1,489	330
Loss before income taxes	-6,592,004	-5,529,080	-18,773,682	-17,504,968
Benefit from income taxes	1,690,028	2,470,346	5,934,806	6,063,785
Net income (loss)	-4,901,976	-3,058,734	-12,838,876	-11,441,183
Earnings Per Share, Basic and Diluted	($0.09)	($0.06)	($0.25)	($0.22)
Weighted Average Number of Shares Outstanding, Basic and Diluted	52,548,997	51,639,811	52,162,380	51,638,648
As Originally Reported	'	'	'	'
Research and development	'	2,289,820	6,456,736	'
Selling, general and administrative	'	3,138,711	8,827,280	'
Research and development	'	4,170,031	13,817,086	'
Patent preparation fees	'	376,877	1,089,495	'
Total operating expenses	'	7,685,619	23,733,861	'
Operating loss	'	-5,395,799	-17,277,125	'
Change In fair value of common stock warrants	'	-15,032	-126,833	'
Other income, net	'	94	330	'
Loss before income taxes	'	-5,410,737	-17,403,628	'
Benefit from income taxes	'	2,470,346	6,063,785	'
Net income (loss)	'	-2,940,391	-11,339,843	'
Earnings Per Share, Basic and Diluted	'	($0.06)	($0.22)	'
Weighted Average Number of Shares Outstanding, Basic and Diluted	'	51,639,811	51,638,648	'
Adjustments	'	'	'	'
Total operating expenses	'	0	0	'
Operating loss	'	0	0	'
Change In fair value of common stock warrants	'	-118,343	-101,340	'
Loss before income taxes	'	-118,343	-101,340	'
Net income (loss)	'	($118,343)	($101,340)	'
Earnings Per Share, Basic and Diluted	'	$0	$0	'
Weighted Average Number of Shares Outstanding, Basic and Diluted	'	0	0	'